The Athlete's Formulary
TAF
Restricted Access: Healthcare Professionals Only
Access Code
Incorrect access code. Please try again.
Terms of Access and Impartiality Notice
TAF is intended solely for qualified healthcare professionals. It is a medication governance reference and does not provide diagnostic guidance. All clinical decisions, laboratory assessment, and final choice of agent remain the responsibility of the treating clinician. Anti-doping status must be independently verified via wada-ama.org or globaldro.com before any clinical decision with anti-doping implications. Full terms at Terms of Access.
The authors of The Athlete's Formulary receive no payment, financial incentive, or inducement of any kind for the inclusion or recommendation of any product, brand, or manufacturer within this resource. No commercial relationships influence TAF content.
Please confirm your acceptance before continuing.
TAF
The Athlete's Formulary
Medication governance reference for sport
Beta: Restricted Access
Home›Medicines›Antihistamines

Antihistamines

TAF covers athlete-specific governance considerations for antihistamine use in elite sport. Indications, standard dosing, and contraindications are not covered here, refer to the BNF and individual SmPCs. Governance flag
Combination products: Many oral antihistamine products are sold combined with decongestants (for example pseudoephedrine or phenylephrine), caffeine or analgesics. These components have separate anti-doping and performance implications. Check every ingredient of the dispensed product. The WADA status of the antihistamine does not apply to the combination. Verify via GlobalDRO.
Evidence Ratings: A Systematic review / meta-analysis of RCTs   B Individual RCT or strong observational data   C Cohort / mechanistic human studies   D Case series / preclinical / operational   E In vitro / theoretical
Class Profiles
Comparative Table
First Generation
First Generation: Class Overview
Chlorphenamine · Promethazine
WADA: Not Prohibited 2026▾
1. Athlete-Specific Considerations

Sedating antihistamines with anticholinergic activity. The main sport-relevant concerns are drowsiness, slowed reaction time and reduced sweating in heat. Sedation can persist beyond the dosing window, so effects around morning training, competition and travel are relevant.

Heat tolerance: Reduced sweating may add to heat strain in hot or humid conditions. Inferred from anticholinergic pharmacology, not a labelled effect. D

Over-the-counter exposure: Common in cold, flu and sleep products, where co-ingredients need separate checking.

2. Formulation and Route

Form: Oral tablets and oral solutions. Parenteral formulations exist and are not covered here.

Route: Oral

Travel: Tablets and oral solutions: no restrictions. Carry original packaging with dispensing label. Oral solutions: check airline carry-on requirements for liquids. Verify local regulatory status of the agent before international travel.

3. Dose and Timing Around Training

Sedation and psychomotor impairment are the main timing considerations. Effects on reaction time, coordination and concentration may be present when training, competing or travelling, including the morning after an evening dose. See individual agent notes.

4. Performance-Impact Risks

Sedation: Drowsiness, dizziness, blurred vision and psychomotor impairment. Impairment can be present without the athlete feeling drowsy.

Skill and reaction-time tasks: Reaction time, coordination and concentration may be reduced.

Heat: Reduced sweating may add to heat strain. D

5. Recovery-Impact Risks

Daytime sedation may affect training quality and daytime function. Anticholinergic effects include dry mouth and urinary retention. Effects on sleep architecture are not claimed here.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See individual agent SmPCs for full interaction profiles.

Alcohol: Increased sedation. Avoid concurrent use.

Sedatives, hypnotics and anxiolytics: Increased sedative effect.

MAOIs: Contraindicated within 14 days.

Sedating supplements (for example melatonin, valerian): Additive sedation is plausible and not directly studied.

Other antihistamine-containing products: Avoid duplication, including cough and cold products.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

Product names, legal category and availability vary by country. Verify the local product and its ingredients. Check combination products on GlobalDRO.

9. Club Cost Consideration

See individual agent notes.

10. Allergens, Religious and Lifestyle

See individual agent notes.

INDIVIDUAL AGENTS

Chlorphenamine
Sedating · Tablets and oral solution · P
P ▾
1. Athlete-Specific Considerations

First-generation sedating antihistamine.

Licensed indications include symptomatic control of allergic conditions that respond to antihistamines, such as hay fever and urticaria.

Sedation and impaired concentration are the main sport-relevant effects. Impairment can be present without the athlete feeling drowsy.

Reduced sweating may add to heat strain in hot or humid conditions. Inferred from anticholinergic pharmacology, not a labelled effect. D

Common in over-the-counter cold and flu combinations, where co-ingredients need separate checking.

2. Formulation and Route

Form: Oral tablets and oral solution. Parenteral formulations exist and are not covered here.

Route: Oral

Legal category: P

Travel: Tablets: no restrictions. Oral solutions: check airline carry-on requirements for liquids. Carry original packaging with dispensing label.

SmPC: Chlorphenamine 4mg tablets SmPC ↗

3. Dose and Timing Around Training

Sedation and psychomotor impairment are the main timing considerations. Anticholinergic effects may seriously affect the ability to drive and use machinery. Effects on reaction time, coordination and concentration may be present when training, competing or travelling, including the morning after an evening dose.

4. Performance-Impact Risks

Sedation: Drowsiness, dizziness, blurred vision and psychomotor impairment.

Skill and reaction-time tasks: Reaction time, coordination and concentration may be reduced, with or without the athlete feeling drowsy.

Heat: Reduced sweating may add to heat strain in hot or humid conditions. Inferred from anticholinergic pharmacology, not a labelled effect. D

5. Recovery-Impact Risks

Daytime sedation may affect training quality and daytime function.

Dry mouth is common. Urinary retention is listed with unknown frequency.

Effects on sleep architecture are not claimed here.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

Alcohol: Effects may be increased. Avoid concurrent use.

Hypnotics and anxiolytics: Increased sedative effect.

Phenytoin: Chlorphenamine inhibits its metabolism and can lead to phenytoin toxicity.

MAOIs: Anticholinergic effects intensified. Contraindicated within 14 days.

Other antihistamine-containing products: Avoid duplication, including cough and cold products.

Sedating supplements (for example melatonin, valerian): Additive sedation is plausible and not directly studied.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

P in the UK. Pharmacy supervision required.

Product names and availability vary by country. Verify local requirements before international travel or competition. Check combination products on GlobalDRO.

9. Club Cost Consideration

Approximately £0.03 per 4mg tablet.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com

Promethazine
Sedating · Tablets, oral solution and injection · P/POM
P POM Rx ▾
1. Athlete-Specific Considerations

First-generation sedating phenothiazine antihistamine.

Licensed indications include symptomatic treatment of allergic conditions of the upper respiratory tract and skin, antiemetic use, and short-term treatment of insomnia in adults. Sominex is licensed for correction of temporary disturbances of sleep pattern.

More sedating than chlorphenamine, with effects lasting up to 12 hours. Next-day effects on alertness, reaction time and coordination are a particular concern.

Reduced sweating may add to heat strain in hot or humid conditions. Inferred from anticholinergic pharmacology, not a labelled effect. D

Also used for travel sickness and sleep, so use may fall outside allergy care.

2. Formulation and Route

Form: Oral tablets (10mg, 25mg), oral solution and solution for injection. Parenteral use is not covered here.

Route: Oral

Legal category: P/POM

Travel: Tablets: no restrictions. Oral solutions: check airline carry-on requirements for liquids. Carry original packaging with dispensing label.

SmPC: Phenergan 25mg tablets SmPC ↗ · Sominex SmPC ↗

3. Dose and Timing Around Training

Effects can last up to 12 hours. Sedation, dizziness and blurred vision may be present when training, competing or travelling, including the morning after an evening dose.

4. Performance-Impact Risks

Sedation: Sedation or somnolence is very common. Dizziness and blurred vision are also reported.

Skill and reaction-time tasks: Reaction time, coordination and concentration may be reduced.

Heat: Reduced sweating may add to heat strain in hot or humid conditions. Inferred from anticholinergic pharmacology, not a labelled effect. D

QT interval: Phenothiazines may prolong the QT interval. Consider where an athlete has other QT-relevant factors.

Photosensitivity: Avoid strong sunlight and UV light during treatment and shortly after, relevant to outdoor training.

5. Recovery-Impact Risks

Daytime sedation may affect training quality and daytime function.

Dry mouth, constipation and urinary retention are reported, each with unknown frequency.

Effects on sleep architecture are not claimed here.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

Alcohol: Intensifies sedation. Avoid.

Sedatives, hypnotics, tricyclic antidepressants and anticholinergics: Effects enhanced.

Antipsychotics: Increased risk of neuroleptic malignant syndrome.

QT-prolonging drugs: Caution.

CYP2D6 substrates (for example amitriptyline): Levels may rise.

Drugs that lower seizure threshold: Caution.

MAOIs: Avoid within 14 days.

Magnesium, aluminium and calcium antacids: Separate by at least 2 hours.

Sedating supplements (for example melatonin, valerian): Additive sedation is plausible and not directly studied.

Skin allergy testing and urine pregnancy tests: Stop at least 72 hours before skin tests (false negatives). May cause false results in immunological urine pregnancy tests.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

P/POM in the UK.

Product names, legal category and availability vary by country, and sleep-aid versions differ by market. Verify local requirements before international travel or competition.

9. Club Cost Consideration

Approximately £0.03 per 10mg tablet and £0.04 per 25mg tablet. Sominex 20mg (P) is approximately £0.24 per tablet in the pack of 8 and £0.17 in the pack of 16.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com

Second Generation
Second Generation: Class Overview
Cetirizine · Desloratadine · Fexofenadine · Loratadine
WADA: Not Prohibited 2026▾
1. Athlete-Specific Considerations

Second-generation antihistamines, generally less sedating than first-generation agents. Individual response varies, so sedation and fatigue remain relevant around training, competition and travel. See individual agent notes.

Over-the-counter exposure is common, including in combination allergy and cold products, where co-ingredients need separate checking.

2. Formulation and Route

Form: Oral tablets (all agents). Oral solutions are available for some agents.

Route: Oral

Travel: Tablets: no restrictions. Oral solutions: check airline carry-on requirements for liquids. Carry original packaging with dispensing label. Verify local regulatory status of the agent before international travel.

3. Dose and Timing Around Training

Sedation and fatigue vary by agent. Alertness may be affected around training, competition and travel. See individual agent notes.

4. Performance-Impact Risks

Sedation and fatigue: Vary by agent. Cetirizine is reported to cause somnolence more often than placebo. Desloratadine, fexofenadine and loratadine are described as having no or negligible influence on driving and machine use.

Skill and reaction-time tasks: Individual response should be known before relying on performance in precision tasks.

5. Recovery-Impact Risks

Daytime fatigue or somnolence may affect training quality and daytime function. See individual agent notes.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See individual agent SmPCs for full interaction profiles.

Alcohol: Precautions vary by agent. See individual agent notes.

CNS depressants: Additional reduction in alertness is possible with cetirizine.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

Product names, legal category and availability vary by country. Verify the local product and its ingredients. Check combination products on GlobalDRO.

9. Club Cost Consideration

See individual agent notes.

10. Allergens, Religious and Lifestyle

See individual agent notes.

INDIVIDUAL AGENTS

Cetirizine
Less sedating · Tablets and oral solution · GSL/P/POM
P POM Rx ▾
1. Athlete-Specific Considerations

Second-generation antihistamine.

Licensed indications include relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis and relief of symptoms of chronic idiopathic urticaria.

Somnolence is reported more often than with placebo, making it the agent in this class most associated with sedation.

Caution is advised with alcohol and other CNS depressants.

2. Formulation and Route

Form: Oral tablets (10mg) and oral solution.

Route: Oral

Legal category: GSL/P/POM

Travel: Tablets: no restrictions. Oral solutions: check airline carry-on requirements for liquids. Carry original packaging with dispensing label.

SmPC: Cetirizine 10mg tablets SmPC ↗

3. Dose and Timing Around Training

Somnolence is reported more often than with placebo. Driving tests showed no clinically relevant effects at the recommended dose, but patients who experience somnolence are advised against hazardous activities and machinery. Alertness may be affected around training, competition and travel.

4. Performance-Impact Risks

Somnolence: The main concern. Mild to moderate in most cases.

CNS depressants: Alcohol and other CNS depressants may cause additional reductions in alertness.

Epilepsy: Caution in epilepsy or risk of convulsions.

5. Recovery-Impact Risks

Daytime somnolence may affect daytime function.

Caution where there is a predisposition to urinary retention, as cetirizine may increase that risk.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

Alcohol: Precaution recommended. No clinically significant interaction at therapeutic doses.

Other CNS depressants: Additional reduction in alertness.

Pseudoephedrine and theophylline: No interaction found.

Allergy testing: A 3-day wash-out is needed beforehand.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

GSL/P/POM in the UK, depending on pack size.

Product names, legal category and availability vary by country. Verify local requirements before international travel or competition.

9. Club Cost Consideration

Approximately £0.02 per 10mg tablet.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com

Desloratadine
Less sedating · Tablets · POM
POM Rx ▾
1. Athlete-Specific Considerations

Second-generation antihistamine.

Licensed indications include relief of symptoms of allergic rhinitis and urticaria in adults and adolescents aged 12 years or older.

The SmPC describes no or negligible influence on the ability to drive and use machines. Fatigue is common and somnolence is very rare.

2. Formulation and Route

Form: Oral tablets (5mg).

Route: Oral

Legal category: POM

Travel: No restrictions. Carry original packaging with dispensing label.

SmPC: Desloratadine 5mg tablets SmPC ↗

3. Dose and Timing Around Training

The SmPC describes no or negligible influence on the ability to drive and use machines. Fatigue is common, so alertness and energy may be affected around training, competition and travel.

4. Performance-Impact Risks

Fatigue: Common. Somnolence is very rare.

Seizures: Caution with a medical or familial history of seizures.

5. Recovery-Impact Risks

Fatigue may affect daytime function and training tolerance.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

Alcohol: Caution advised. Cases of alcohol intolerance and intoxication have been reported after marketing.

Erythromycin and ketoconazole: No clinically relevant interaction seen in trials.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

8. International and Jurisdictional

POM in the UK. Prescription required.

Product names, legal category and availability vary by country. Verify local requirements before international travel or competition.

9. Club Cost Consideration

Approximately £0.05 per 5mg tablet.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com

Fexofenadine
Less sedating · Tablets · P/POM
P POM Rx ▾
1. Athlete-Specific Considerations

Second-generation antihistamine.

Licensed indications include relief of symptoms of seasonal allergic rhinitis (120mg) and of chronic idiopathic urticaria (180mg), in adults and children aged 12 years and older.

Drowsiness is common and reported at a rate similar to placebo. The SmPC states it is unlikely to affect the ability to drive or use machines.

2. Formulation and Route

Form: Oral tablets (120mg, 180mg).

Route: Oral

Legal category: P/POM

Travel: No restrictions. Carry original packaging with dispensing label.

SmPC: Fexofenadine 120mg SmPC ↗ · Fexofenadine 180mg SmPC ↗

3. Dose and Timing Around Training

The SmPC states it is unlikely to affect the ability to drive or use machines. Individual response is worth knowing before complex tasks. Aluminium and magnesium antacids should be separated by 2 hours.

4. Performance-Impact Risks

Drowsiness: Common, at a rate similar to placebo in trials.

Cardiovascular: Antihistamines as a class have been associated with tachycardia and palpitations, relevant in patients with cardiovascular disease.

5. Recovery-Impact Risks

Headache and dizziness are common. No other recovery-specific effects are described.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

Aluminium and magnesium hydroxide antacids: Reduced absorption. Leave 2 hours between doses.

Erythromycin and ketoconazole (P-gp inhibitors): 2 to 3 times increase in plasma fexofenadine levels.

Apalutamide (weak P-gp inducer): Lowers exposure.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

8. International and Jurisdictional

P/POM in the UK, depending on strength.

Product names, legal category and availability vary by country. Verify local requirements before international travel or competition.

9. Club Cost Consideration

Approximately £0.04 per 120mg tablet and £0.10 per 180mg tablet.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com

Loratadine
Less sedating · Tablets and oral solution · GSL/P/POM
P POM Rx ▾
1. Athlete-Specific Considerations

Second-generation antihistamine.

Licensed indications include symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

The SmPC describes no or negligible influence on the ability to drive and use machines, although some people may feel drowsy. Somnolence was the most frequent reaction above placebo in adult trials.

2. Formulation and Route

Form: Oral tablets (10mg) and oral solution.

Route: Oral

Legal category: GSL/P/POM

Travel: Tablets: no restrictions. Oral solutions: check airline carry-on requirements for liquids. Carry original packaging with dispensing label.

SmPC: Loratadine 10mg tablets SmPC ↗

3. Dose and Timing Around Training

The SmPC describes no or negligible influence on the ability to drive and use machines. Some people may feel drowsy, which could affect alertness around training, competition and travel.

4. Performance-Impact Risks

Somnolence: The most frequent reaction above placebo in adult trials.

5. Recovery-Impact Risks

Fatigue is listed as very rare. No other recovery-specific effects are described.

6. Medicine and Supplement Interactions

Selected interactions relevant to common athlete use patterns. Not exhaustive. See SmPC for full interaction profile.

CYP3A4 and CYP2D6 inhibitors: May raise loratadine levels and increase adverse events.

Alcohol: No potentiating effect on psychomotor performance was found.

Skin allergy testing: Stop at least 48 hours beforehand.

7. WADA Status and Anti-Doping Risk Mitigation

WADA: Not Prohibited 2026.

Combination products (for example with decongestants, caffeine or analgesics) have separate anti-doping and performance implications. Check every ingredient of the dispensed product on GlobalDRO.

8. International and Jurisdictional

GSL/P/POM in the UK, depending on pack size.

Product names, legal category and availability vary by country. Verify local requirements before international travel or competition.

9. Club Cost Consideration

Approximately £0.02 per 10mg tablet.

Verify current pricing at bnf.nice.org.uk.

10. Allergens, Religious and Lifestyle

Excipients vary by manufacturer. Verify per dispensed product.

Vegetarian: Verify per dispensed product.

Vegan: Verify per dispensed product.

Halal: Verify per dispensed product.

Kosher: Verify per dispensed product.

For product-specific allergen or excipient queries, contact info@medsontrack.com